en · de · es · pt
peptide-index.peptides5388.com › News › Background And Mechanism Of Sr9009 — Reference Sheet

Background And Mechanism Of Sr9009 — Reference Sheet

By Editorial Desk · published 2025-10-20 · last reviewed 2025-12-08 · News

If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-12-08. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Detection, Regulation, and Misconceptions

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule ligand; not a hormone or peptide
Molecular formulaC20H24ClN3O4SReported for the free base
CAS Registry Number1379686-30-2Unique chemical identifier
Common synonymsSR9009; stenabolicStenabolic is informal and not an official name
Reported targetsREV-ERBα and REV-ERBβNuclear receptors linked to circadian and metabolic regulation

Background and Receptor Pharmacology

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Related pages on this site

Analytical Detection and Stability

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

SR9009 Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

Notes from published material

== PDI-PIXE-MS == Particle desorption ionisation particle-induced X-ray emission mass spectrometry (PIXE-MS) is a technique which combines PIXE with mass spectrometry of molecules. Elemental determinations are performed by PIXE with a heavy ion, such as oxygen, while simultaneously collecting the molecular ions for mass analysis in a quadrupole mass spectrometer, or time-of-flight (TOF) instrument. ICP-MS only determines elemental constituents using mass spectrometry, not molecular information. Sequential scanning may be done with a hydrogen ion beam and then a heavy ion beam to desorb and ionise the analyte sample. This technique allows for the analysis of both the elemental constituents as well as the molecular ions, or molecular speciation, present in a sample, using a heavy ion beam. This makes use, typically, of a 4 MeV accelerator with samples prepared in glycerol, on carbon felt.

Food packaging is created through the use of a wide variety of plastics and metals, papers, and glass materials. Recycling these products differs from the act of literally reusing them because the recycling process has its own algorithm, which includes collecting, sourcing, processing, manufacturing and marketing these products. According to the Environmental Protection Agency of the United States, the recycling rate has been steadily on the rise, with data reporting that, in 2018, the recycling rate of generated packaging and containers was 53.9 percent. Recycling rates for glass and metal packaging fluctuate considerably based on regional infrastructure, collection methods, and public engagement. In the European Union, glass packaging attains an average recycling rate of approximately 80%. Conversely, the United States exhibits a lower glass recycling rate of roughly 31%, mainly due to contamination and inadequate sorting capabilities. Metal packaging, especially aluminum and steel, typically has superior recycling efficiency. In the EU, aluminum beverage cans achieve recycling rates of approximately 76%. Both materials exhibit superior recycling rates and quality in comparison to plastic and paper. The product's quality and safety are the package's most important responsibility. However, there have been growing demands for packaging to be designed, manufactured, consumed, and recycled in a more sustainable fashion due to the increasing pollution connected with packaging and food waste.

India is a megadiverse country, a term employed for 17 countries that host high biological diversity and contain many species indigenous, or endemic, to them. India is the habitat for 8.6% of all mammals, 13.7% of bird species, 7.9% of reptile species, 6% of amphibian species, 12.2% of fish species, and 6.0% of all flowering plant species. Fully a third of Indian plant species are endemic. India also overlaps four of the world's 34 biodiversity hotspots, or regions that display significant habitat loss in the presence of high endemism. India's densest forests, such as the tropical moist forest of the Andaman Islands, the Western Ghats, and Northeast India, occupy about 3% of its land area. Moderately dense forest, whose canopy density is between 40% and 70%, occupies 9.39% of India's land area. It predominates in the temperate coniferous forest of the Himalayas, the moist deciduous sal forest of eastern India, and the dry deciduous teak forest of central and southern India. India has two natural zones of thorn forest, one in the Deccan Plateau, immediately east of the Western Ghats, and the other in the western part of the Indo-Gangetic plain, now turned into rich agricultural land by irrigation, its features no longer visible. Among the Indian subcontinent's notable indigenous trees are the astringent Azadirachta indica, or neem, which is widely used in rural Indian herbal medicine, and the luxuriant Ficus religiosa, or peepul, which is displayed on the ancient seals of Mohenjo-daro, and under which the Buddha is recorded in the Pali canon to have sought enlightenment.

== Societies and associations == Caribbean Labour Solidarity, based in London, UK Chicago Linguistic Society Chinese Language Society Christian Legal Society Communist League of Struggle, US, 1931–1937

Sources: en.wikipedia.org

Further detail

Achene – most commonly seen in aggregate fruits (e.g., strawberry, see below) Capsule – (Brazil nut: botanically, it is not a nut) Caryopsis – (cereal grains, including wheat, rice, oats, barley) Cypsela – an achene-like fruit derived from the individual florets in a capitulum: (dandelion) Fibrous drupe – (coconut, walnut: botanically, neither is a true nut.) Follicle – follicles are formed from a single carpel, and opens by one suture: (milkweed); commonly seen in aggregate fruits: (magnolia, peony) Legume – (bean, pea, peanut: botanically, the peanut is the seed of a legume, not a nut) Loment – a type of indehiscent legume: (sweet vetch or wild potato) Nut – (beechnut, hazelnut, acorn (of the oak): botanically, these are true nuts) Samara – (ash, elm, maple key) Schizocarp, see below – (carrot seed) Silique – (radish seed) Silicle – (shepherd's purse) Utricle – (beet, Rumex) Fruits in which part or all of the pericarp (fruit wall) is fleshy at maturity are termed fleshy simple fruits. Types of fleshy simple fruits, (with examples) include:

The Cochrane reviews on the treatment of ADHD in children, adolescents, and adults with pharmaceutical amphetamines stated that short-term studies have demonstrated that these drugs decrease the severity of symptoms, but they have higher discontinuation rates than non-stimulant medications due to their adverse side effects. However, a 2025 meta-analytic systematic review of 113 randomized controlled trials found that stimulant medications were the only intervention with robust short-term efficacy, and were associated with lower all-cause treatment discontinuation rates than non-stimulant medications (e.g., atomoxetine). A Cochrane review on the treatment of ADHD in children with tic disorders such as Tourette syndrome indicated that stimulants in general do not make tics worse, but high doses of dextroamphetamine could exacerbate tics in some individuals.

In 2018, the International Union for Conservation of Nature (IUCN) assessed the white shark as vulnerable worldwide, citing a population decline of 30–49% since approximately 1859. The species was further described as "moderately depleted" in 2021. The biggest threats to white sharks are accidental catching in fishing nets and the use of shark control measures—such as nets and traps—near beaches in Australia and South Africa. They nevertheless maintain a high survival rate when released from such gear. To regulate international trade, the species is listed under CITES Appendix II, requiring permits for the exchange of any specimens or parts. While a 2025 study estimated the global population at a minimum of roughly 5,800 individuals, co-author Gavin Naylor suggests the actual figure may be closer to 20,000.

Sources: en.wikipedia.org

Background from the literature

=== Other drugs === Certain medications can decrease the absorption of orally consumed vitamin B12, including colchicine, extended-release potassium products, and antibiotics such as gentamicin, neomycin and tobramycin. Anti-seizure medications phenobarbital, pregabalin, primidone and topiramate are associated with lower than normal serum vitamin concentration. However, serum levels were higher in people prescribed valproate. In addition, certain drugs may interfere with laboratory tests for the vitamin, such as amoxicillin, erythromycin, methotrexate and pyrimethamine.

Modafinil's precise mechanism of action in narcolepsy and other sleep disorders remains incompletely understood. Nevertheless, in animals and in humans modafinil acts primarily as an atypical dopamine transporter (DAT) inhibitor or dopamine reuptake inhibitor (DRI), producing a modest increase in extracellular dopamine in cortical and striatal brain regions without inducing the rapid dopamine signaling characteristic of classical stimulants such as amphetamine or cocaine. This modest dopaminergic effect is accompanied by broader downstream activation of arousal-related neurotransmitter systems. Modafinil increases noradrenergic tone in wakefulness-promoting nuclei and indirectly engages hypothalamic orexin and histamine pathways, which together help stabilize the sleep–wake regulatory network and support sustained alertness. Although modafinil interacts with multiple neurotransmitter systems, its exact mode of action at the molecular level remains uncertain. At the level of neural circuits, modafinil enhances glutamatergic excitatory transmission and reduces GABAergic inhibitory output within cortical and thalamic pathways, shifting network activity toward excitation and cortical activation while exerting minimal direct effects on classical monoamine receptors.

=== 25 April === At least 11 people were killed in an RSF drone strike in Atbara that hit a displaced persons camp and energy facilities. RSF shelling from Salha in Omdurman hit the SAF's general headquarters in Khartoum.

The Accreditation Commission for Health Care (ACHC) is a United States-based non-profit health care accrediting organization. It represents an alternative to the Joint Commission and CHAP, The Community Health Accreditation Program. ACHC was established in 1985 by home care health providers to create an accreditation option which was more focused on the needs of small providers. The process began in Raleigh, North Carolina, with the group incorporated in August 1986. The first accredited organization was awarded certification in January 1987. The company began offering services on a national level in 1996. Today, ACHC offers nineteen accreditation programs, nine of which are CMS approved (Acute Care Hospital, Ambulatory Surgery Center, Clinical Laboratory, Critical Access Hospital, DMEPOS, Home Health, Home Infusion Therapy, Hospice, Renal Dialysis).

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Is SR9009 approved for human use?

No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.

How does SR9009 differ from natural REV-ERB ligands?

Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.

Network